CTOs on the Move

BrainsWay

www.brainsway.com

 
BrainsWay is an Israeli company with international operations that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a noninvasive treatment for depression.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.brainsway.com
  • 1 Van de Graaff Drive Suite 405
    Burlington, MA USA 01803
  • Phone: 844.386.7001

Executives

Name Title Contact Details

Similar Companies

Granite Recovery Centers

Granite Recovery Centers are the New England drug and alcohol addiction treatment centers you can rely on for recovery. Call 855.712.7784 today to learn more!

Mylan Pharmaceuticals Inc

Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of

CARE Counseling

At Care Counseling, were dedicated to ensuring you and your loved ones can rest easy knowing that were here to help.

Purdue Pharma

Purdue Pharma is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and ADHD. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.